Physician profile
Robert Belser
NPI 1821055104
$1,415.71
in general payments reported to CMS, 2019-2025
16 companies · $81.82 in 2025
The $81.82 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $176 · 2021: $278 · 2022: $231 · 2023: $360 · 2024: $138 · 2025: $81.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $651.91 | 2019-2025 | |
| Intersect Ent, INC. | $125.33 | 2021-2022 | |
| Inspire Medical Systems, INC. | $118.58 | 2023 | Inspire |
| Genzyme Corporation | $75.38 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $72.13 | 2021-2023 | |
| Stryker Corporation | $68.73 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $57.97 | 2019-2021 | |
| Baxter Healthcare | $41.93 | 2023 | Perclot |
| Glaxosmithkline, LLC. | $35.39 | 2022-2025 | Nucala |
| Boston Scientific Corporation | $33.48 | 2024 | Watchman Flx |
| Aerin Medical INC. | $27.17 | 2020 | |
| Smith+Nephew, INC. | $24.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.96 | 2019 | |
| Hikma Pharmaceuticals USA | $21.80 | 2023 | Ryaltris |
| Vertex Pharmaceuticals Incorporated | $20.71 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Belser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.